Topoisomerase 1, known for its role in unwinding DNA during transcription and the target of chemotherapy drugs Camptosar (irinotecan, Pfizer Inc.) and Hycamtin (topotecan, GlaxoSmithKline plc.), plays a role in coordinating the innate immune response, and inhibiting it could be a therapeutic strategy in diseases characterized by excessive inflammation, scientists reported in the April 29, 2016, issue of Science.